title: Is there justification for 4 cycles of consolidation therapy in AML?
abstract: The concept of postremission therapy in acute myeloid leukemia is quite old, dating back to a trial conducted in 1988 by the Cancer and Leukemia Group B. Yet even with more than 20 years of investigation into the optimal number of cycles for consolidation therapy, the answer is still not entirely clear. Dose intensity also has an impact on the number of courses of consolidation therapy administered, as do the cytogenetics of the patients. This review examines how to direct the future of consolidation therapy outside of allogeneic transplantation and discusses the issues to consider in choosing the number of courses of consolidation, including the effect minimal residual disease may have in guiding decisions regarding consolidation treatment.
authors.affiliation: National Center of Tumor Diseases, Clinical Trials Center, Im Neuenheimer Feld 130.3, Marsilius Arkaden, Heidelberg 69120, Germany. Electronic address: richard.schlenk@nct-heidelberg.de.
authors.forename: Richard F
authors.initials: RF
authors.lastname: Schlenk
mesh_terms: D060830:Consolidation Chemotherapy / Q000379:methods*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D018365:Neoplasm, Residual; D000090243:Nucleophosmin
keywords: AML; Acute myeloid leukemia; CBF; Consolidation; Core binding factor; Genetic landscape; MRD; Minimal residual disease; Mutation status; NPM1; Nucleophosmin 1